A Phase I Single Arm Trial Combining Radiotherapy and Temozolomide With Dichloracetate (DCA) [sodium dichloroacetate] in Patients With Newly Diagnosed Glioblastoma Multiform Tumours.
Withdrawn prior to enrolment
Phase of Trial: Phase I
Latest Information Update: 24 Feb 2016
At a glance
- Drugs Sodium dichloroacetate (Primary) ; Temozolomide
- Indications Glioblastoma
- Focus Adverse reactions
- 31 Aug 2018 Biomarkers information updated
- 21 Sep 2011 Status changed from not yet recruiting to withdrawn prior to recruitment as reported by ClinicalTrials.gov.
- 21 Jul 2008 New trial record.